# US 2026/0263573 A1 · Tumor Immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0263573 A1
- Document ID: US20260263573A1
- Status: Published application
- Kind: A1
- Application number: 18/833,462
- Filed: 2022-06-17
- Published: 2026-09-10
- Earliest claimed: 2022-01-26
- Assignees: PingShan Translational Medicine Center, Shenzhen Bay Laboratory; Peking University Shenzhen Graduate School
- Applicants: PingShan Translational Medicine Center, Shenzhen Bay Laboratory; Peking University Shenzhen Graduate School
- Inventors: Zigang Li; Feng Yin; Yaping Zhang; Leying Jiang; Zhaodi Liu
- Web page: https://patentgrep.com/patent/US20260263573A1

## CPC

- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61P 35/00: Antineoplastic agents
- A61K 39/0011: {Cancer antigens}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/82: {Colon}
- A61K 2039/876: {Skin, melanoma}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed is a composition comprising a closed-loop peptide comprising at least two methionines and at least two sulfonium centers; and a conjugate of a negatively charged immunoadjuvant and a peptide.

## Claims

### Claim 1

A composition comprising:
a closed-loop peptide comprising at least two methionines and at least two sulfonium centers; and
a conjugate formed by a negatively charged immunoadjuvant and a peptide.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the negatively charged immunoadjuvant is selected from the group consisting of a nucleic acid immunoadjuvant, an activator of an immune pathway and an adjuvant having an effect of blocking an immunosuppressive pathway, preferably CpG1826, ploy (I: C) and siRNA/shRNA for silencing an immunosuppressive pathway or activating an immune pathway.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the negatively charged immunoadjuvant comprises at least 20 nucleotides.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the negatively charged immunoadjuvant comprises a sequence of SEQ ID NO 6.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the peptide is an antigen peptide, preferably an antigen peptide of melanoma B16-OVA (OVA257-264: Ac-SIINFEKL) and a neoantigen peptide of MC-38 tumor cells (Adpgk: Ac-ELASMTNMELMSS).

### Claim 6 (depends on 1)

The composition of claim 1, wherein the peptide comprises at least 8 amino acids.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the peptide comprises a sequence of SEQ ID NO 2, a sequence of SEQ ID NO 3, or a sequence of SEQ ID NO 4.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the closed-loop peptide comprises at least 9 amino acids.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the closed-loop peptide comprises a sequence of SEQ ID NO 1.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the conjugate is a reversible covalent conjugate.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the composition has a particle size of 50 nm to 200 nm.

### Claim 12 (depends on 1)

A process for preparing the composition of claim 1, comprising:
dissolving a linear peptide comprising at least two methionines in a weakly acidic polar solution and adding a closed-loop reagent to obtain a closed-loop peptide;
mixing an immunoadjuvant with a sulfonium peptide under basic conditions to obtain a conjugate by an addition reaction; and
mixing the conjugate with the closed-loop peptide to obtain the composition.

### Claim 13 (depends on 12)

The process of claim 12, wherein the immunoadjuvant is a nucleic acid adjuvant, preferably an immunoadjuvant having a sulfhydryl terminus, more preferably a nucleic acid immunoadjuvant comprising a sequence of SEQ ID NO 6.

### Claim 14 (depends on 12)

The process of claim 12, wherein the sulfonium peptide is selected from the group consisting of a sulfonium peptide having an alkynyl terminus and a sulfonium peptide having a vinyl terminus, preferably selected from the group consisting of a peptide comprising a sequence of SEQ ID NO 2, a peptide comprising a sequence of SEQ ID NO 3 and a peptide comprising a sequence of SEQ ID NO 4.

### Claim 15 (depends on 12)

The process of claim 12, wherein the molar ratio of the immunoadjuvant to the sulfonium peptide is from 1:2 to 1:10.

### Claim 16 (depends on 12)

The process of claim 12, wherein the molar ratio of the immunoadjuvant to the closed-loop peptide is 1:50 to 1:400.

### Claim 17 (depends on 12)

The process of claim 12, wherein the conjugate is self-assembled with the closed-loop peptide to obtain the composition.

### Claim 18 (depends on 12)

The process of claim 12, wherein the immunoadjuvant is mixed with a sulfonium peptide under basic conditions at 4 to 28° C. to obtain a conjugate by an addition reaction.

### Claim 19 (depends on 12)

The process of claim 12, wherein the linear peptide comprising at least two methionines comprises a sequence of SEQ ID NO 1.

### Claim 20 (depends on 1)

A method for treating or preventing a tumor, comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of the composition of claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the tumor is selected from the group consisting of melanoma and colon cancer.

### Claim 22 (depends on 20)

The method of claim 20, wherein the subject is a mammal, preferably a human.

### Claim 23 (depends on 20)

The method of claim 20, further comprising administering to the subject another agent for preventing or treating a tumor.

### Claim 24 (depends on 23)

The method of claim 23, wherein the agent is selected from the group consisting of a chemotherapeutic drug, a biological drug or any combination thereof, preferably a small molecule chemotherapeutic drug, a peptide drug, an antibody drug or any combination thereof, more preferably paclitaxel, PD-1 monoclonal antibody, PD-L1 monoclonal antibody, a biological drug having a targeted therapeutic effect or any combination thereof.

### Claim 25 (depends on 1)

A method for activating immunity, comprising administering to a subject in need thereof an effective amount of the composition of claim 1.

### Claim 26 (depends on 25)

The method of claim 25, wherein the immunity is tumor immunity.

### Claim 27 (depends on 25)

The method of claim 25, wherein the immunity is cellular immunization.

### Claim 28

A nanoparticle comprising:
a closed-loop peptide comprising at least two methionines and at least two sulfonium centers; and
a conjugate formed by a negatively charged immunoadjuvant and a peptide,
wherein the closed-loop peptide is self-assembled with the conjugate to form the nanoparticle.
